<< Back to News

New FDA Approval for PERJETA

Genentech is excited to share the news of the FDA approval of PERJETA in combination with trastuzumab and chemotherapy as:

·  Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer 

·  Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

The FDA approval letter for PERJETA can be found at

 https://www.genentech-access.com/PERJETA